Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

A.B. Delaloye; C. Antonescu; T. Louton; J. Kuhlmann; A. Hagenbeek

Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

Translated title of the contribution: Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

A.B. Delaloye
, C. Antonescu
, T. Louton
, J. Kuhlmann
, A. Hagenbeek

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Original language	Undefined/Unknown
Pages (from-to)	1837-1843
Number of pages	7
Journal	Journal of Nuclear Medicine
Volume	50
Issue number	11
Publication status	Published - 2009

Cite this

@article{e67ba91b40a74ebdba7fa5181acecaff,

title = "Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.",

author = "A.B. Delaloye and C. Antonescu and T. Louton and J. Kuhlmann and A. Hagenbeek",

year = "2009",

language = "Undefined/Unknown",

volume = "50",

pages = "1837--1843",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "11",

}

Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. / Delaloye, A.B.; Antonescu, C.; Louton, T. et al.
In: Journal of Nuclear Medicine, Vol. 50, No. 11, 2009, p. 1837-1843.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

AU - Delaloye, A.B.

AU - Antonescu, C.

AU - Louton, T.

AU - Kuhlmann, J.

AU - Hagenbeek, A.

PY - 2009

Y1 - 2009

M3 - Article

SN - 0161-5505

VL - 50

SP - 1837

EP - 1843

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 11

ER -